CapsoVision Misses Q3 Estimates With 15-Cent Loss, Revenue Flat at $3.57M
CV sits 39% above its 52-week low of $4.5.
Summary
CapsoVision posted a Q3 adjusted loss of 15 cents a share, a penny worse than the 14-cent consensus and wider than the 17-cent loss a year ago on a reported basis. Revenue came in at $3.57 million, up 0.8% but below the $3.76 million analysts expected, and the company swung to a $7.34 million quarterly loss. The results land alongside the 10-Q filed tonight, which formally states substantial doubt about the company's ability to continue as a going concern — a red flag for a micro-cap that has been leaning on its $100 million ATM and a September $18 million direct offering at $5.69. Analysts have already cut their mean earnings estimate by about 20.8% over the past three months, and the stock is down 41.3% year to date. The lone bright spot remains the September FDA clearance of the AI Highlights tool for CapsoCam Plus, but it has not yet shown up in revenue.
At the time of this announcement, CV was trading at $6.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $333.6M. The 52-week trading range was $4.50 to $15.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.